Alpine Global Management’s Pacific Biosciences PACB Stock Holding History

Alpine Global Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,848	Closed	-$17.7K	–	407
2025 Q3	$17.7K	Buy	+13,848	New	+$18.8K	﹤0.01%	187
2023 Q1	–	Sell	-14,192	Closed	-$116K	–	342
2022 Q4	$116K	Buy	+14,192	New	+$122K	0.04%	198
2020 Q1	–	Sell	-62,143	Closed	-$319K	–	383
2019 Q4	$319K	Sell	62,143 -337,857	-84%	-$1.72M	0.07%	265
2019 Q3	$2.06M	Buy	400,000 +150,000	+60%	+$839K	0.53%	25
2019 Q2	$1.51M	Buy	250,000 +151,780	+155%	+$1.06M	0.44%	31
2019 Q1	$710K	Buy	+98,220	New	+$710K	0.21%	37

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alpine Global Management's PACB Position: Q4 2025 in Review

Alpine Global Management sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 13,848 shares — an estimated $17.7K sold.

Alpine Global Management first reported a position in PACB in Q1 2019 and held it in 6 quarters. The position peaked at $2.06M in Q3 2019. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

Alpine Global Management reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
Alpine Global Management sold 13,848 Pacific Biosciences shares in Q4 2025, an estimated $17.7K.
Alpine Global Management first reported a position in Pacific Biosciences in Q1 2019 and held it in 6 quarters.
Alpine Global Management's Pacific Biosciences position peaked at $2.06M in Q3 2019.
215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Alpine Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.